title: The relationship between HLA-G and viral loads in non-responder HCV-infected patients after combined therapy with IFN-α2α and ribavirin.
abstract: Hepatitis C disease is a virus mediated infection causing major health problem worldwide. Conversions of immune surveillance play an important role in response to virus clearance. Immune modulating molecules such as HLA-G and IL-10 that convert immune response toward Th2 may play a role to inhibit response from combined therapy with IFN-α2α and ribavirin. The objective of this study was to investigate the expression of HLA-G and IL-10 in responder and non-responder HCV positive patients. In this study, characteristics of the virus and 48 responder and non-responder patients in response to the combined therapy with IFN-α2α and ribavirin were analyzed. The expression levels of HLA-G and IL-10 were conducted using real-time PCR. Also, soluble HLA-G in both groups of patients and healthy individuals were determined by enzyme-linked immunosorbent assay. According to the obtained data, HCV 1a was the predominant genotype in responder and non-responder patients. Expression levels of HLA-G and IL-10 in non-responder group was significantly more than responder and control groups (P<0.001). Additionally, expression levels of HLA-G and IL-10 were remarkably higher compared to healthy individuals at the beginning of treatment. Soluble HLA-G in non-responder patients was noticeably increased in comparison to responder patients after treatment (P<0.05). These findings suggest that elevation of HLA-G and IL-10 in HCV infected patients may play an important role in response to combined therapy with IFN-α2α and ribavirin.
authors.affiliation: Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Samaneh
authors.initials: S
authors.lastname: Khorrami
authors.affiliation: Department of Medical Immunology, Faculty of Medical Science, Tarbait Modares University, Tehran, Iran.
authors.forename: Hemn
authors.initials: H
authors.lastname: Mohammadpour
authors.affiliation: Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Kiana
authors.initials: K
authors.lastname: Shahzamani
authors.affiliation: Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
authors.forename: Mahin Nikougoftar
authors.initials: MN
authors.lastname: Zarif
authors.affiliation: Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Amir Hoshang
authors.initials: AH
authors.lastname: Sharifi
authors.affiliation: Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Shahin
authors.initials: S
authors.lastname: Merat
authors.affiliation: Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: h.Poustchi@gmail.com.
authors.forename: Hossein
authors.initials: H
authors.lastname: Poustchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D005786:Gene Expression Regulation; D059951:HLA-G Antigens / Q000235:genetics / Q000378:metabolism*; D016174:Hepacivirus / Q000187:drug effects / Q000502:physiology*; D006526:Hepatitis C / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000627:therapeutic use*; D019562:Viral Load / Q000235:genetics; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D059951:HLA-G Antigens; D016898:Interferon-alpha; D016753:Interleukin-10; D012254:Ribavirin
keywords: HLA-G; IFN-α2α; IL-10; Responder and non-responder patients; Ribavirin